X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc. (XFOR) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
xfor · stock forecast · 13 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 13 Wall Street analysts in the past 3 months
Buy
13 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$12.00
Consensus
$12.00
+223.5% upside
Low
$12.00
Median: $12 · Last Close: $3.71
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $3.65 | ↓ 1.57% |
1-day model range: $3.6–$3.7. Peak: $3.7 (-1.57%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · XFOR · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-12-05 | Stifel | Maintains | Buy→Buy |
| 2025-11-10 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-08-29 | Stifel | Maintains | Buy→Buy |
| 2025-08-13 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-05-02 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-27 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-26 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2025-02-07 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-01-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-14 | HC Wainwright & Co. | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on X4 Pharmaceuticals, Inc. (XFOR) stock. Of the recent 44 rating actions, 1 were upgrades and 1 were downgrades. 13 analysts currently cover XFOR.
Analyst Recommendation Trends
XFOR analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$10M
↓ 90.6% YoY
Revenue Next Year
$10M
↑ 0.8% YoY
EPS This Year
$-0.73
EPS Next Year
$-0.80
↑ 9.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast XFOR EPS of $-0.73 for the current fiscal year, based on estimates from 3 analysts. The XFOR revenue forecast is $10M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The XFOR stock forecast is supported by two independent data sources: analyst consensus ratings from 13 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus XFOR price target is $12.00 (+223.5% upside), with an analyst consensus of Buy.
The XFOR short-term stock prediction for tomorrow is $3.65 (-1.57%).
X4 Pharmaceuticals, Inc. trades on NASDAQ under the ticker XFOR. The XFOR stock outlook for 2027 is broadly positive, supported by a Buy consensus among 92% of covering analysts.
Frequently asked questions
XFOR forecast · 8 questionsAccording to 13 Wall Street analysts, the average 12-month XFOR price target is $12.00, with a high forecast of $12.00 and a low of $12.00. The median price target is shown in the chart above when available. This implies +223.5% potential upside from the current price of $3.71.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.